The Pulse
UK Accepts All 44 AI Healthcare Regulation Recommendations
The UK government has accepted all 44 recommendations from its National Commission into the Regulation of AI in Healthcare. The MHRA will test ongoing safety monitoring through AI Airlock Phase 3, while a full implementation roadmap is due
AI.info Team · Written with AI ·
Faster access, closer scrutiny
The UK government says it wants promising AI tools to reach NHS patients sooner; the doctors-led commission whose recommendations it has accepted argues that approval cannot be a one-time check. On 6 October, ministers accepted all 44 recommendations for regulating AI in healthcare, including a shift toward monitoring products throughout their use. The policy aims to speed adoption while requiring stronger evidence about how tools perform in real clinical settings.
“But innovation must never come at the expense of patient safety,” Health Innovation Minister James Frith said. The announcement sets out initial actions, not a completed overhaul: the government plans to publish a full roadmap with timelines and responsibilities by Spring 2027.
From one-off approval to ongoing monitoring
The National Commission, launched by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2025, published its recommendations on 10 September 2026. Its central argument is that AI products can change over time and perform differently depending on where and how they are used, making a single pre-market assessment insufficient. The commission’s work drew on an engagement programme involving more than 12,000 patients, clinicians and members of the public.
The government response calls for a more proportionate, lifecycle-based system. That includes stronger checks after deployment, clearer evidence requirements and better monitoring of changes in safety and performance. It also commits to work on fair access, patient involvement, workforce training, accountability and routes for patients to seek redress.
Early access comes with evidence-gathering
The MHRA will explore staged authorisation pathways that could let some AI tools enter NHS use earlier under close supervision while further real-world evidence is collected. It also plans draft guidance by December 2026 on managing changes to AI-enabled medical devices as they adapt, and will consult next year on how those products should be classified and whether they qualify as medical devices.
The response acknowledges that AI products do not all fall under the same rules: some count as medical devices, while others are covered by data-protection, professional or organisational frameworks. The government says the existing medical-device regulations need updating to reflect software and AI. Any broader changes will require work across the MHRA, NHS bodies, other regulators and health departments in the UK’s four nations.
AI Airlock tests the approach
Alongside the policy response, the MHRA has opened applications for the third phase of AI Airlock, its regulatory sandbox for AI-enabled medical devices. This phase will focus on post-market monitoring and lifecycle regulation, testing how devices can be tracked and managed once in use. The programme has secured three years of additional government funding; applications are open now, a webinar for prospective applicants follows on 22 October 2026, and the first group of developers will be selected in November 2026.
A cross-system Programme Board will oversee delivery and meet quarterly. The government’s response accepts the recommendations, but the detailed roadmap is still to come; for now, the clearest near-term commitments are the December draft guidance, next year’s classification consultation and the Airlock’s work on monitoring deployed devices.